BloggingStocks (Free subscription) | 23/11/2009
Filed under: Microsoft (MSFT) , Abbott Laboratories (ABT) , Chasing Value , Stocks to Buy The march toward year end continues as three more stocks are reviewed in a search for the eventual 2010 stock picks. This year there will be nine stocks with a new wrinkle, I will add one naked put. These options have contributed to a mind-boggling return on my 2009 portfolio, exceeding 200% to date. This has...
PharmaGossip (Free subscription) | 19/11/2009
Cholesterol pills Vytorin from Merck & Co. and Lipitor from Pfizer Inc. worked no better than simvastatin, a cheaper generic medicine, at keeping patients out of the hospital for heart attacks or stroke, a study found. Researchers with UnitedHealth Group Inc. ’s pharmacy benefits unit Prescription Solutions analyzed medical claims of 30,000 patients taking one of the three drugs. They found...
DeviceSpace (Free subscription) | 18/11/2009
Reuters -- U.S. regulators have warned Abbott Laboratories Inc about poor manufacturing standards at a molecular diagnostics plant. The U.S. Food and Drug Administration, in an Aug. 12 letter released on Tuesday, said an inspection of the company's Des Plaines, Illinois, facility had revealed production shortfalls, resulting in adulterated devices.
DeviceSpace (Free subscription) | 17/11/2009
The ABSORB trial is a prospective, non-randomized (open label), two-phase study designed to enroll approximately 130 patients from Australia, Belgium, Denmark, France, the Netherlands, New Zealand, Poland and Switzerland. Key endpoints of the study include assessments of safety - MACE and stent thrombosis rates - at 30 days; six, nine, 12 and 18 months; and two years, with additional annual clinical...
PharmaGossip (Free subscription) | 16/11/2009
By Bill Berkrot and Ransdell Pierson ORLANDO, Fla., Nov 16 (Reuters) - The good news for Merck & Co's ( MRK.N ) Zetia cholesterol fighter is that doctors do not seem unduly concerned about its latest setback in a clinical trial. The bad news is they think patient anxiety will cause its sales to drop anyway. Physicians interviewed after release of data from a small study in which Abbott Laboratories'...
Science - The Post Chronicle (Free subscription) | 16/11/2009
Abbott Laboratories' Niaspan appeared to be more effective and safer than Merck & Co's Zetia as a supplementary cholesterol treatment to statins....
Chicago Breaking News (Free subscription) | 16/11/2009
Their reported Radio City Music Hall showdown in New York may be off, but former Presidents George W. Bush and Bill Clinton are scheduled for a joint appearance to talk biotechnology next May in the more low-key environs of the Second City. The Biotechnology Industry Organization's annual meeting May 3-6 in Chicago will serve as backdrop for the two former leaders in what the group says will have...
SeekingAlpha.com (Free subscription) | 15/11/2009
Dividend Inc. submits: On October 9, 2009 , I created a list of ten Dividend Achievers that I felt were the best investments at the time. After having passed the 1 month period, I feel that it is necessary to review the performance of the stocks that were on that list. As with the original article I will show the performance based on those that were ranked from 1st to 10th ( chart ). Wal-Mart ( WMT...
Madd Money (Free subscription) | 13/11/2009
For the “Off The Charts” segment, Cramer went up against his colleague at TheStreet.com Dan Fitzpatrick over the charts of health care stocks, Abbott Laboratories (NYSE:ABT) and Johnson & Johnson (NYSE:JNJ), the former which Cramer holds in his charitable trust. Fitzpatrick thinks that Abbott Labs is about to beak out to the upside, while Johnson [...]
MarketIntelligenceCenter.com (Free subscription) | 12/11/2009
Abbott Laboratories (NYSE: ABT) opened at $53.39. So far today, the stock has hit a low of $53.01 and a high of $53.80. ABT is now trading at $53.23, down $0.04 (-0.08%). Over the last 52 weeks the stock has ranged from a low of $41.27 to a high of $57.39. Wedbush Morgan initiated ABT at Outperform this morning, giving the stock a $62 pri...
Chicago Tribune (Free subscription) | 12/11/2009
Bolstering its stable of drugs derived from human cells, Abbott Laboratories said Thursday that it will acquire the worldwide rights to an experimental pain drug from Dutch biotech firm PanGenetics BV for $190 million.
Rocky Mount Telegram - Business (Free subscription) | 12/11/2009
NORTH CHICAGO, Ill. — Abbott Laboratories said Thursday it is buying a potential chronic pain ...
Fiercebiotech (Free subscription) | 12/11/2009
The Dutch biotech PanGenetics has forged a $190 million licensing pact with Abbott Laboratories for a promising early-stage pain therapy--and it's getting $170 million of that upfront. The antibody binds to nerve growth factor, blocking a chemical released at the site of injuries. And the early-stage trial of PG110 for chronic pain could be supplemented with new trials for lower back pain, cancer...
Miami Herald (Free subscription) | 12/11/2009
Abbott Laboratories said Thursday it is buying a potential chronic pain drug from PanGenetics BV for as much as $190 million.
San Diego Union (Free subscription) | 12/11/2009
Abbott Laboratories said Thursday it is buying a potential chronic pain drug from PanGenetics BV for as much as $190 million.
Videos